Over the past decade, immune checkpoint inhibitors, such as PD-1, PD-L1, and anti-angiogenic monoclonal antibodies, have revolutionized the result of advanced cancer (Peng C. et al., 2020). The gene discussed is PDCD1; the disease is cancer.